{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:55:11Z","timestamp":1762941311639,"version":"3.45.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["32003B_175559"],"award-info":[{"award-number":["32003B_175559"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Bladder carcinomas are immunogenic, and patients with bladder cancer benefit from immune checkpoint therapy. This is correlated to a high tumor mutation burden, which provides a higher number of neoepitopes that can be recognized by tumor-specific CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) is used to treat non-muscle invasive bladder cancer (NMIBC), but its mechanism of action remains elusive. Most lymphocytes appearing in the urine of BCG-treated patients are CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells though preclinical studies showed that CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells are also necessary for BCG treatment efficacy. It is currently unknown which proportion of patients with non-metastatic bladder cancer develop a spontaneous antitumor CD8\n                      <jats:sup>+<\/jats:sup>\n                      response, and if BCG treatment influences this response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In a first cohort of 15 NMIBC and 9 muscle invasive bladder cancer patients, we used IFN-\n                      <jats:italic>y<\/jats:italic>\n                      ELISPOT assays to screen for the presence of anti-neoepitope CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in the blood, tumor and urine. In a second cohort of 4 NMIBC patients, we analyzed the features and specificity of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells infiltrating the tumoral or bladder tissues before and after BCG using single cell transcriptomic analyses. A total of 31 tumor-infiltrating CD8\n                      <jats:sup>+<\/jats:sup>\n                      clonotypes were screened against neoepitopes and tumor cDNA libraries.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      9 out of 24 patients from the first cohort mounted a spontaneous and functional anti-neoepitope T-cell response in blood and\/or tumor. In 5 patients from this cohort who were treated with BCG, no neoantigen-specific T cells were detected in urine during treatment. In the second cohort, 6 out of 6 TCRs from exhausted CD8\n                      <jats:sup>+<\/jats:sup>\n                      TILs from one patient recognized 5 different neoepitopes. T-cell receptor (TCR) repertoire analyses indicated that the frequencies of these tumor-specific T cells did not increase after BCG instillations, neither in the bladder nor in the blood. None of the 25 other TCRs of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells recognized tumor-specific antigens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      We show that one third of patients with non-metastatic bladder cancer mount a spontaneous and functional anti-neoepitope CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell response detectable in blood or tumor. In 4 patients with NMIBC, BCG treatment did not boost or induce the anti-neoepitope response, suggesting alternative mechanisms of action for its efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1627914","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:50:27Z","timestamp":1762941027000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Walther","family":"Brochier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Cesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orian","family":"Bricard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"van Baren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rald","family":"Hames","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Dauguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Dano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia-Cristina","family":"Rodrigues-Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Masnada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Genolet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Harari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beat","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Lucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Nardelli-Haefliger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre G.","family":"Coulie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Derr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":". Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.12.6188","article-title":"An antigen recognized by autologous CTLs on a human bladder carcinoma","volume":"160","author":"Gueguen","year":"1998","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801022","article-title":"Identification of neoantigen-reactive tumor-infiltrating lymphocytes in primary bladder cancer","volume":"202","author":"Leko","year":"2019","journal-title":"J Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1038\/s41467-022-29342-0","article-title":"Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma","volume":"13","author":"Holm","year":"2022","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0226-y","article-title":"The multifaceted immune regulation of bladder cancer","volume":"16","author":"Schneider","year":"2019","journal-title":"Nat Rev Urol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004421117","article-title":"Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-gamma signaling","volume":"117","author":"Antonelli","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4161\/onci.20526","article-title":"Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients","volume":"1","author":"Pieraerts","year":"2012","journal-title":"Oncoimmunology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41467-018-03301-0","article-title":"Sensitive and frequent identification of high avidity neo-epitope specific CD8 (+) T cells in immunotherapy-naive ovarian cancer","volume":"9","author":"Bobisse","year":"2018","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3364","article-title":"MiXCR: software for comprehensive adaptive immunity profiling","volume":"12","author":"Bolotin","year":"2015","journal-title":"Nat Methods"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0654-x","article-title":"Orchestrating single-cell analysis with Bioconductor","volume":"17","author":"Amezquita","year":"2020","journal-title":"Nat Methods"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100194","article-title":"Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting","volume":"2","author":"Schmidt","year":"2021","journal-title":"Cell Rep Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0022-1759(03)00209-6","article-title":"Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC","volume":"278","author":"Atanackovic","year":"2003","journal-title":"J Immunol Methods"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz114","article-title":"The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads","volume":"47","author":"Liao","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp450","article-title":"ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data","volume":"25","author":"Morgan","year":"2009","journal-title":"Bioinformatics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1101\/861054","article-title":"Calling somatic SNVs and indels with mutect2","author":"Benjamin","year":"2019","journal-title":"bioRxiv 861054"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: fast and accurate calling of germline and somatic variants","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Methods"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.763248","article-title":"Comprehensive analyses of the immunological and prognostic roles of an IQGAP3AR\/let-7c-5p\/IQGAP3 axis in different types of human cancer","volume":"9","author":"Yuan","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research","year":"2014","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2014.006","article-title":"Full-length RNA-seq from single cells using Smart-seq2","volume":"9","author":"Picelli","year":"2014","journal-title":"Nat Protoc"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46102","article-title":"Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients","volume":"121","author":"Baitsch","year":"2011","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl5447","article-title":"Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers","volume":"375","author":"Lowery","year":"2022","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26139","article-title":"Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity","volume":"9","author":"Morimoto","year":"2018","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205356","article-title":"CDK12: an emerging therapeutic target for cancer","volume":"71","author":"Lui","year":"2018","journal-title":"J Clin Pathol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","volume":"25","author":"Scheper","year":"2019","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2003.00104.x","article-title":"HLA class I expression in bladder carcinomas","volume":"62","author":"Cabrera","year":"2003","journal-title":"Tissue Antigens"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1882","article-title":"Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells","volume":"73","author":"Redelman-Sidi","year":"2013","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","article-title":"Prevention of tuberculosis in macaques after intravenous BCG immunization","volume":"577","author":"Darrah","year":"2020","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188288","article-title":"T cell recognition of Mycobacterium tuberculosis peptides presented by HLA-E derived from infected human cells","volume":"12","author":"McMurtrey","year":"2017","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3298","article-title":"The burgeoning family of unconventional T cells","volume":"16","author":"Godfrey","year":"2015","journal-title":"Nat Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004880","article-title":"Vdelta2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.11.124","article-title":"Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer","volume":"181","author":"Bisiaux","year":"2009","journal-title":"J Urol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0157","article-title":"BCG-induced tumor immunity requires tumor-intrinsic CIITA independent of MHC-II","volume":"10","author":"Redelman-Sidi","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069892","article-title":"Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis","volume":"8","author":"Elsasser","year":"2013","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197410)34:8+<1532::AID-CNCR2820340827>3.0.CO;2-H","article-title":"Immunotherapy of Guinea pig cancer with BCG","volume":"3","author":"Zbar","year":"1974","journal-title":"Johns Hopkins Med J Suppl"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":". J Urol"},{"key":"B52","article-title":"Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells","volume":"52","author":"Lattime","year":"1992","journal-title":"Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1627914\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:50:29Z","timestamp":1762941029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1627914\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2025.1627914"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1627914","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"article-number":"1627914"}}